HOME >> BIOLOGY >> NEWS
Drugs limit deadly side effects of graft-versus-host disease

aft-versus-host disease each year

"An allogeneic bone marrow transplant is a double-edged sword," says Pavan Reddy, M.D., an assistant professor of internal medicine in the U-M Medical School and corresponding author of the PNAS paper. "The good side is the graft-versus-leukemia (GVL) effect, which means that T cells from donated bone marrow, called the graft, will attack and kill any cancer cells remaining in the patient. GVL represents the most potent known form of immune therapy against malignant diseases. Without GVL, the cancer will most likely return.

"The bad side is graft-versus-host disease. In GVHD, T cells from donated bone marrow, in concert with inflammatory cytokines, attack the patient's skin, liver and gastrointestinal tract," Reddy explains. "The key is to block the inflammatory cytokines, which exacerbate GVHD, but leave the cancer-killing donor T cells untouched, since they are vital for an effective GVL response."

In previous research published in the June 2002 issue of Nature Medicine, Ferrara and Reddy, with colleagues from the U-M Cancer Center, discovered that inflammatory cytokines are the major cause of GVHD-induced cell damage. Since then, they have been searching for ways to neutralize cytokines or block their production. Their current work with HDAC inhibitors is an extension of this earlier research.

"No one has looked at this class of drugs in a post-bone-marrow-transplant setting before, but two other groups have found similar anti-inflammatory effects in mouse models used for research on lupus and sepsis," says Reddy. "So now there are several studies showing that HDAC inhibitors are more than just anti-tumor agents."

Reddy and his U-M research colleagues conducted two sets of experiments with strains of laboratory mice commonly used in research related to bone marrow transplants. In the first experiment, three groups of mice were given standard bone marrow transplants. Mice received bone marr
'"/>

Contact: Sally Pobojewski
pobo@umich.edu
734-615-6912
University of Michigan Health System
27-Feb-2004


Page: 1 2 3 4 5

Related biology news :

1. Drugs, electronics, and green catalysts: The chemical year in review
2. Drugs from sea study finds sponge health link to bacteria
3. Drugs on tap
4. Discovery Of A Molecule That Controls Bile Acids May Lead To New Cholesterol Drugs
5. UT Southwestern Researchers Find Way To Control Gene Activity, Opening Way For Cancer Drugs
6. New Findings On Receptor Regulation May Lead To Better Drugs For Diabetes
7. NASA Research Helps Map Protein Structures -- Key In The Development Of New Disease-Fighting Drugs
8. 15 Drugs, Dyes And Other Chemicals Newly Listed As Known Or Likely Human Carcinogens
9. Cholesterol Lowering Drugs Stall Disease Progression In People With Below-Average Blood Cholesterol Level
10. Some AIDS Patients May Show Resistance To Sulfa Drugs
11. Researchers Discover Existing Drugs May Prevent Enlarged Hearts

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drugs limit deadly side effects graft versus host disease

(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, ... devices with specialties in single use solutions, headquartered in ... MedConx, Inc. (a California corporation with ... San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility in ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
(Date:6/29/2015)... , ... June 29, 2015 , ... ... CAGR of around 19% during the forecast period (2015 to 2020). The market ... upsurge in government and corporate funding for R&D. However, lack of adequate healthcare ...
(Date:6/29/2015)... -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using ... cell therapy treatments for central nervous system diseases, announced ... the NASDAQ Capital Market under the symbol "CUR." The ... NYSE MKT until the market close on July 10, ... to commence on July 13, 2015. ...
(Date:6/29/2015)... June 29, 2015   For the seventh year running, ... assess their overall digital maturity called the Multichannel ... companies are not maturing fast enough. While it,s true ... numerous ways overall and customers are increasingly "digital natives", ... digital customer engagement.  ...
(Date:6/26/2015)... 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... all nominees listed in the management information circular ... 2015 Annual Meeting of Shareholders, held earlier today, ... the following 5 nominees proposed by management were ... until the Company,s next Annual Meeting of Shareholders ...
Breaking Biology Technology:Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3
Cached News: